Tour de France Officials Address Doping Protocol Discrepancies

Anti-doping authorities overseeing the Tour de France have pushed back against allegations that race leadership is showing favoritism toward French cyclist Paul Seixas. The scrutiny comes as rivals questioned why the 19-year-old home favorite, currently sitting fourth in the general classification, has avoided the late-night testing sessions that other top contenders have faced.

While the entire peloton, including Seixas and his Peloton Interactive, Inc.-backed Decathlon CMA CGM squad, underwent standard biological passport testing on Monday evening, the specific nature of the testing has drawn complaints. Notably, race leader Tadej Pogačar and Jonas Vingegaard, who has since withdrawn from the event, were both subjected to nocturnal controls, a measure that has not yet been applied to Seixas.

The French anti-doping agency has denied that it plays any direct role in selecting which specific riders are tested or when those tests occur, aiming to quell rising tensions within the peloton regarding fairness and protocol.

For investors following the sports industry, Peloton Interactive is currently trading down 1.72% today, with shares at $6.24. The connected fitness company holds a market capitalization of approximately $2.75 billion as it maintains its visibility in the cycling sector through team sponsorship.

What to watch

• Further statements from the UCI regarding testing transparency for the remainder of the race.
• Peloton’s upcoming quarterly earnings to gauge the impact of its sponsorship investments.

Source: original release